Latent Tuberculosis Infection in Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00507754|
Recruitment Status : Completed
First Posted : July 27, 2007
Last Update Posted : September 26, 2011
1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- To examine the factors associated with positive response to T-SPOT.TB and the TST (tuberculin skin test) in patients with anergy.
- To determine the impact of immunosuppressive and antineoplastic therapy on the screening performance of T-SPOT.TB and the TST in cancer patients.
|Condition or disease||Intervention/treatment|
|Advanced Cancer||Other: T-SPOT TB test|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||24 participants|
|Official Title:||Latent Mycobacterium Tuberculosis Infection Among Cancer Patients|
|Study Start Date :||June 2007|
|Primary Completion Date :||May 2011|
|Study Completion Date :||May 2011|
Latent Tuberculosis Infection
Patients with cancer at risk for developing active tuberculosis (TB).
Other: T-SPOT TB test
Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
- Rate of Positive Results of T-SPOT.TB (%) [ Time Frame: Study period 2 Years ]Number participants with postitive T-SPOT.TB test results compared to total positive results, derived from Center for Disease Control (CDC) Criteria used for LTBI positive skin test (i.e. a tuberculin skin test (TST) with 5 mm or more of induration). For those individuals with >5 mm induration on TST, chest radiograph performed. Fisher's exact test used to assess the association between categorical variables and the testing results of T-SPOT.TB or TST.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507754
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Amar Safdar, MD||M.D. Anderson Cancer Center|